0
Skip to Content
BioscienceLA
About
Why LA
Mission
What We Do
Stakeholders
Sponsors
BioscienceLA Week
Events
Our Team
Join Us
Programs
BioFutures Internship Program
UCLA Health TechQuity
Resources
Job Resources
Funders
Organizations
Spaces
@ Culver City
About
Community
Become a Member
Host an Event
BioscienceLA
About
Why LA
Mission
What We Do
Stakeholders
Sponsors
BioscienceLA Week
Events
Our Team
Join Us
Programs
BioFutures Internship Program
UCLA Health TechQuity
Resources
Job Resources
Funders
Organizations
Spaces
@ Culver City
About
Community
Become a Member
Host an Event
Folder: About
Back
Why LA
Mission
What We Do
Stakeholders
Sponsors
BioscienceLA Week
Events
Our Team
Join Us
Folder: Programs
Back
BioFutures Internship Program
UCLA Health TechQuity
Folder: Resources
Back
Job Resources
Funders
Organizations
Spaces
Folder: @ Culver City
Back
About
Community
Become a Member
Host an Event
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Ecosystem News Sree Batchu 5/28/21 Ecosystem News Sree Batchu 5/28/21

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Read More
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate
Industry News Sree Batchu 5/10/21 Industry News Sree Batchu 5/10/21

Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate

Read More
A Liquid 'Shield' Used on Ebola Now Has FDA Clearance to Make Handling COVID Tests Safer for Lab Workers
Industry News Sree Batchu 3/11/21 Industry News Sree Batchu 3/11/21

A Liquid 'Shield' Used on Ebola Now Has FDA Clearance to Make Handling COVID Tests Safer for Lab Workers

Read More
FDA Approves Gilead/Kite's Yescarta as First CAR-T for Follicular Lymphoma
Industry News Sree Batchu 3/8/21 Industry News Sree Batchu 3/8/21

FDA Approves Gilead/Kite's Yescarta as First CAR-T for Follicular Lymphoma

Read More
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
Ecosystem News Jessica Barnette 7/24/20 Ecosystem News Jessica Barnette 7/24/20

U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Read More
 
BioscienceLA

Subscribe

Receive our bi-weekly newsletter and occasional special alerts.

Thank you! Have something of interest to the ecosystem? Email info@biosciencela.org with your ideas.

 

ABOUT 

WHAT WE DO

OUR TEAM

OUR PROGRAMS

CONTACT

RESOURCES

NEWSROOM

RESOURCES

PRESS

Bioscience Los Angeles County, Inc. (“BioscienceLA”) is an independent 501(c)(3) not-for-profit organization formed by Los Angeles County in 2018 with backing from Amgen, PhRMA, Richard Lundquist, Richard Merkin, City of Hope, and Cedars-Sinai, among others. It was formed to create, enable, and promote an enviable, thriving, and vibrant life sciences ecosystem in Greater Los Angeles to produce economic and societal benefits in the region.

 

© 2024 Bioscience Los Angeles County Inc. All Rights Reserved.  Terms of Use  |  Privacy Policy